Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine.

Barry DT, Fazzino T, Necrason E, Ginn J, Fiellin LE, Fiellin DA, Moore BA.

J Addict Med. 2016 Sep-Oct;10(5):352-6. doi: 10.1097/ADM.0000000000000247.

PMID:
27504926
2.

Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Subst Abuse. 2015 Sep 10;9:59-80. doi: 10.4137/SART.S30120. Review.

3.

Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.

Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O'Grady KE, Jaffe JH.

Drug Alcohol Depend. 2015 Nov 1;156:133-8. doi: 10.1016/j.drugalcdep.2015.09.001.

4.

Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.

Brady KT, McCauley JL, Back SE.

Am J Psychiatry. 2016 Jan;173(1):18-26. doi: 10.1176/appi.ajp.2015.15020262. Review.

5.

Counselor training and attitudes toward pharmacotherapies for opioid use disorder.

Aletraris L, Edmond MB, Paino M, Fields D, Roman PM.

Subst Abus. 2016;37(1):47-53. doi: 10.1080/08897077.2015.1062457.

6.

Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.

Woodcock EA, Lundahl LH, Greenwald MK.

Drug Alcohol Depend. 2015 Jan 1;146:89-96. doi: 10.1016/j.drugalcdep.2014.11.016.

7.

Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients.

McHugh RK, Fitzmaurice GM, Carroll KM, Griffin ML, Hill KP, Wasan AD, Weiss RD.

Drug Alcohol Depend. 2014 Dec 1;145:121-6. doi: 10.1016/j.drugalcdep.2014.10.002.

8.

Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743.

9.

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, Weiss RD, Trivedi M.

Addict Behav. 2015 Feb;41:20-8. doi: 10.1016/j.addbeh.2014.09.021.

10.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Review.

11.

Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.

Mauger S, Fraser R, Gill K.

Neuropsychiatr Dis Treat. 2014 Apr 7;10:587-98. doi: 10.2147/NDT.S39692. Review.

12.

Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Rieckmann TR, Abraham AJ, Kovas AE, McFarland BH, Roman PM.

Addict Behav. 2014 May;39(5):889-96. doi: 10.1016/j.addbeh.2014.01.016.

13.

Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response.

Dvoriak S, Karachevsky A, Chhatre S, Booth R, Metzger D, Schumacher J, Chychula N, Pecoraro A, Woody G.

Drug Alcohol Depend. 2014 Apr 1;137:62-7. doi: 10.1016/j.drugalcdep.2014.01.008.

14.

Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: a longitudinal study.

Tsui JI, Anderson BJ, Strong DR, Stein MD.

Am J Drug Alcohol Abuse. 2014 Mar;40(2):163-9. doi: 10.3109/00952990.2013.848875.

15.

Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial.

Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO.

J Consult Clin Psychol. 2014 Jun;82(3):448-59. doi: 10.1037/a0035798.

16.

Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies.

Wachholtz A, Gonzalez G, Boyer E, Naqvi ZN, Rosenbaum C, Ziedonis D.

Subst Abuse Rehabil. 2011 Aug 18;2:145-62. doi: 10.2147/SAR.S12944. Review.

17.

Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.

Genberg BL, Gillespie M, Schuster CR, Johanson CE, Astemborski J, Kirk GD, Vlahov D, Mehta SH.

Addict Behav. 2013 Dec;38(12):2868-73. doi: 10.1016/j.addbeh.2013.08.008.

18.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266.

19.

A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.

Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O'Connor PG, Schottenfeld RS.

Am J Med. 2013 Jan;126(1):74.e11-7. doi: 10.1016/j.amjmed.2012.07.005.

20.

Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.

McNicholas LF, Holbrook AM, O'Grady KE, Jones HE, Coyle MG, Martin PR, Heil SH, Stine SM, Kaltenbach K.

Addiction. 2012 Nov;107 Suppl 1:91-7. doi: 10.1111/j.1360-0443.2012.04043.x.

Items per page

Supplemental Content

Support Center